vimarsana.com

Page 8 - Peginterferon Lambda News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Eiger to add Peginterferon Lambda to Covid-19 trial in Brazil

Eiger to add Peginterferon Lambda to Covid-19 trial in Brazil 04 May 2021 (Last Updated May 4th, 2021 12:09) Eiger BioPharmaceuticals has said that its investigational agent, Peginterferon Lambda, will be added to the Phase III TOGETHER platform study of Covid-19 outpatients in Brazil. Share Article The study is enrolling Covid-19 patients at 11 sites in Brazil. Credit: Wilfried Pohnke from Pixabay. Eiger BioPharmaceuticals has said that its investigational agent, Peginterferon Lambda, will be added to the Phase III TOGETHER platform study of Covid-19 outpatients in Brazil. A type III interferon (IFN), Lambda induces immune responses required for developing host protection during viral infections. Eiger licensed the therapeutic from Bristol-Myers Squibb.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.